Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 571
- Registration Number
- NCT04410796
- Locations
- 🇺🇸
University of Washington (Data Collection Only), Seattle, Washington, United States
🇺🇸UC Davis Cancer Center (Data Collection Only), Sacramento, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04405674
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-03-23
- Target Recruit Count
- 50
- Registration Number
- NCT04396457
- Locations
- 🇯🇵
National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 870
- Registration Number
- NCT04380636
- Locations
- 🇺🇸
Torrance Memorial Physician Network / Cancer Center ( Site 0093), Torrance, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 0013), Los Angeles, California, United States
🇺🇸Miami VA Healthcare System ( Site 0024), Miami, Florida, United States
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT04372927
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nasser Hanna
- Target Recruit Count
- 100
- Registration Number
- NCT04367311
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 358
- Registration Number
- NCT04351555
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 214
- Registration Number
- NCT04339218
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, Gironde, France
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- iOnctura
- Target Recruit Count
- 210
- Registration Number
- NCT04328844
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇮🇹Humanitas Research Hospital, Rozzano, Milan, Italy
🇮🇹Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04322578
- Locations
- 🇨🇳
Yongchang Zhang, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.